APO Research
Talk to an analyst

APO RESEARCH · REPORT

Secondary Progressive Multiple Sclerosis Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Secondary Progressive Multiple Sclerosis Drug Market Analysis and Forecast 2026-2032

19 December 2025206 pages

Choose your research edition.

Industry ResearchSecondary Progressive Multiple Sclerosis Drug Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Secondary Progressive Multiple Sclerosis Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Secondary Progressive Multiple Sclerosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Secondary Progressive Multiple Sclerosis Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Secondary Progressive Multiple Sclerosis Drug Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Secondary Progressive Multiple Sclerosis Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Secondary Progressive Multiple Sclerosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Secondary Progressive Multiple Sclerosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Secondary Progressive Multiple Sclerosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Secondary Progressive Multiple Sclerosis Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Secondary Progressive Multiple Sclerosis Drug include AB Science SA, Actelion Ltd, F. Hoffmann-La Roche Ltd., Genzyme Corporation, Glialogix, Inc., Immune Response BioPharma, Inc., Innate Immunotherapeutics Ltd, Kyorin Pharmaceutical Co., Ltd. and Mallinckrodt Plc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Secondary Progressive Multiple Sclerosis Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Secondary Progressive Multiple Sclerosis Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Secondary Progressive Multiple Sclerosis Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Secondary Progressive Multiple Sclerosis Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Secondary Progressive Multiple Sclerosis Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Secondary Progressive Multiple Sclerosis Drug sales, projected growth trends, production technology, application and end-user industry.

Secondary Progressive Multiple Sclerosis Drug Segment by Company

AB Science SA

Actelion Ltd

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.

Mallinckrodt Plc

MedDay SA

MedImmune, LLC

Merck KGaA

Meta-IQ ApS

Opexa Therapeutics, Inc.

Xenetic Biosciences (UK) Limited

Biogen, Inc.

Novartis AG

Secondary Progressive Multiple Sclerosis Drug Segment by Type

Etomoxir

Inebilizumab

IB-MS

GLX-1112

DC-TAB

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Application

Hospital

Clinic

Others

Secondary Progressive Multiple Sclerosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Progressive Multiple Sclerosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Secondary Progressive Multiple Sclerosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Progressive Multiple Sclerosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Secondary Progressive Multiple Sclerosis Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Secondary Progressive Multiple Sclerosis Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Secondary Progressive Multiple Sclerosis Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Etomoxir Major Manufacturers Table 3. Inebilizumab Major Manufacturers Table 4. IB-MS Major Manufacturers Table 5. GLX-1112 Major Manufacturers Table 6. DC-TAB Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Manufacturers Table 10. Clinic Major Manufacturers Table 11. Others Major Manufacturers Table 12. Secondary Progressive Multiple Sclerosis Drug Industry Trends Table 13. Secondary Progressive Multiple Sclerosis Drug Industry Drivers Table 14. Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges Table 15. Secondary Progressive Multiple Sclerosis Drug Industry Restraints Table 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2021-2026) Table 20. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2027-2032) Table 21. Global Secondary Progressive Multiple Sclerosis Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 22. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026) & (K Units) Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032) & (K Units) Table 24. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2026) Table 25. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2027-2032) Table 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers, Product Type & Application Table 34. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Secondary Progressive Multiple Sclerosis Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2026) Table 41. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2027-2032) Table 42. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 43. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 44. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 45. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2026) Table 46. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2027-2032) Table 47. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Secondary Progressive Multiple Sclerosis Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2026) Table 53. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2027-2032) Table 54. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 55. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 56. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 57. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2026) Table 58. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2027-2032) Table 59. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Secondary Progressive Multiple Sclerosis Drug Price by Application (2027-2032) & (US$/Unit) Table 61. AB Science SA Company Information Table 62. AB Science SA Business Overview Table 63. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 65. AB Science SA Recent Development Table 66. Actelion Ltd Company Information Table 67. Actelion Ltd Business Overview Table 68. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 70. Actelion Ltd Recent Development Table 71. F. Hoffmann-La Roche Ltd. Company Information Table 72. F. Hoffmann-La Roche Ltd. Business Overview Table 73. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 75. F. Hoffmann-La Roche Ltd. Recent Development Table 76. Genzyme Corporation Company Information Table 77. Genzyme Corporation Business Overview Table 78. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 80. Genzyme Corporation Recent Development Table 81. Glialogix, Inc. Company Information Table 82. Glialogix, Inc. Business Overview Table 83. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 85. Glialogix, Inc. Recent Development Table 86. Immune Response BioPharma, Inc. Company Information Table 87. Immune Response BioPharma, Inc. Business Overview Table 88. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 90. Immune Response BioPharma, Inc. Recent Development Table 91. Innate Immunotherapeutics Ltd Company Information Table 92. Innate Immunotherapeutics Ltd Business Overview Table 93. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 95. Innate Immunotherapeutics Ltd Recent Development Table 96. Kyorin Pharmaceutical Co., Ltd. Company Information Table 97. Kyorin Pharmaceutical Co., Ltd. Business Overview Table 98. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 100. Kyorin Pharmaceutical Co., Ltd. Recent Development Table 101. Mallinckrodt Plc Company Information Table 102. Mallinckrodt Plc Business Overview Table 103. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 105. Mallinckrodt Plc Recent Development Table 106. MedDay SA Company Information Table 107. MedDay SA Business Overview Table 108. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 110. MedDay SA Recent Development Table 111. MedImmune, LLC Company Information Table 112. MedImmune, LLC Business Overview Table 113. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 115. MedImmune, LLC Recent Development Table 116. Merck KGaA Company Information Table 117. Merck KGaA Business Overview Table 118. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 120. Merck KGaA Recent Development Table 121. Meta-IQ ApS Company Information Table 122. Meta-IQ ApS Business Overview Table 123. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 125. Meta-IQ ApS Recent Development Table 126. Opexa Therapeutics, Inc. Company Information Table 127. Opexa Therapeutics, Inc. Business Overview Table 128. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 130. Opexa Therapeutics, Inc. Recent Development Table 131. Xenetic Biosciences (UK) Limited Company Information Table 132. Xenetic Biosciences (UK) Limited Business Overview Table 133. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 135. Xenetic Biosciences (UK) Limited Recent Development Table 136. Biogen, Inc. Company Information Table 137. Biogen, Inc. Business Overview Table 138. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 140. Biogen, Inc. Recent Development Table 141. Novartis AG Company Information Table 142. Novartis AG Business Overview Table 143. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio Table 145. Novartis AG Recent Development Table 146. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 149. North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 150. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 151. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 152. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 153. North America Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 154. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 155. North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 156. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 157. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 158. North America Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. North America Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. North America Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 162. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 163. North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 164. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 165. North America Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 166. United States Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 167. Canada Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 168. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 169. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 170. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 171. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 172. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 173. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 174. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 175. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 176. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 177. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 178. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 179. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 180. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 182. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 183. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 184. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 185. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 186. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 187. Europe Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 188. Germany Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 189. France Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 190. U.K. Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 191. Italy Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 192. Netherlands Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 193. China Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 194. China Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 195. China Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 196. China Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 197. China Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 198. China Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 199. China Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 200. China Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 201. China Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 202. China Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 203. China Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 204. China Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 205. Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 206. Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 207. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 208. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 209. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 210. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 211. Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 212. Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 213. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 214. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 215. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 216. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 217. Asia Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 218. Asia Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 219. Asia Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 220. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 221. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 222. Asia Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 223. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 224. Asia Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 225. Japan Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 226. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 227. India Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 228. Australia Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 229. China Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 230. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 231. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2026) & (US$ Million) Table 232. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2027-2032) & (US$ Million) Table 233. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2026) & (K Units) Table 234. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Type (2027-2032) & (K Units) Table 235. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 236. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 237. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2026) & (US$ Million) Table 238. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2027-2032) & (US$ Million) Table 239. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2026) & (K Units) Table 240. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Application (2027-2032) & (K Units) Table 241. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 242. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 243. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 244. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 245. SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 246. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 247. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021-2026) & (K Units) Table 248. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Country (2027-2032) & (K Units) Table 249. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 250. SAMEA Secondary Progressive Multiple Sclerosis Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 251. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 252. Argentina Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 253. Chile Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 254. Colombia Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 255. Peru Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 256. Saudi Arabia Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 257. Israel Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 258. UAE Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 259. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 260. Iran Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 261. Egypt Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Table 262. Key Raw Materials Table 263. Raw Materials Key Suppliers Table 264. Secondary Progressive Multiple Sclerosis Drug Distributors List Table 265. Secondary Progressive Multiple Sclerosis Drug Customers List Table 266. Research Programs/Design for This Report Table 267. Authors List of This Report Table 268. Secondary Sources Table 269. Primary Sources List of Figures Figure 1. Secondary Progressive Multiple Sclerosis Drug Image Figure 2. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Secondary Progressive Multiple Sclerosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Etomoxir Image Figure 5. Inebilizumab Image Figure 6. IB-MS Image Figure 7. GLX-1112 Image Figure 8. DC-TAB Image Figure 9. Others Image Figure 10. Global Secondary Progressive Multiple Sclerosis Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Secondary Progressive Multiple Sclerosis Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Secondary Progressive Multiple Sclerosis Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Sales (2021-2032) & (K Units) Figure 21. Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Secondary Progressive Multiple Sclerosis Drug Sales YoY (2021-2032) & (K Units) Figure 24. Europe Secondary Progressive Multiple Sclerosis Drug Sales YoY (2021-2032) & (K Units) Figure 25. China Secondary Progressive Multiple Sclerosis Drug Sales YoY (2021-2032) & (K Units) Figure 26. Asia (Excluding China) Secondary Progressive Multiple Sclerosis Drug Sales YoY (2021-2032) & (K Units) Figure 27. South America, Middle East and Africa Secondary Progressive Multiple Sclerosis Drug Sales YoY (2021-2032) & (K Units) Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 35. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2032) Figure 37. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 41. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2032) Figure 43. North America Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2021-2032) Figure 44. North America Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2021-2032) Figure 45. North America Secondary Progressive Multiple Sclerosis Drug Revenue Share by Application (2021-2032) Figure 46. North America Secondary Progressive Multiple Sclerosis Drug Sales Share by Application (2021-2032) Figure 47. North America Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country (2021-2032) Figure 48. North America Secondary Progressive Multiple Sclerosis Drug Sales Share by Country (2021-2032) Figure 49. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2021-2032) Figure 50. Europe Secondary Progressive Multiple Sclerosis Drug Sales Share by Type (2021-2032) Figure 51. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Share by Application (2021-2032) Figure 52. Europe Secondary Progressive Multiple Sclerosis Drug Sales Share by Application (2021-2032) Figure 53. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Share by Country (2021-2032) Figure 54. Europe Secondary Progressive Multiple Sclerosis Drug Sales Share by Country (2021-2032) Figure 55. China Secondary Progressive Multiple Sclerosis Drug Revenue Share by Type (2021-2032) Figure 56. China Secondary Progressive Multiple Sclerosis Drug Sales Shar

Scope & coverage.

Types
  • Etomoxir
  • Inebilizumab
  • IB-MS
  • GLX-1112
  • DC-TAB
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • AB Science SA
  • Actelion Ltd
  • F. Hoffmann-La Roche Ltd.
  • Genzyme Corporation
  • Glialogix, Inc.
  • Immune Response BioPharma, Inc.
  • Innate Immunotherapeutics Ltd
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt Plc
  • MedDay SA
  • MedImmune, LLC
  • Merck KGaA
  • Meta-IQ ApS
  • Opexa Therapeutics, Inc.
  • Xenetic Biosciences (UK) Limited
  • Biogen, Inc.
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Secondary Progressive Multiple Sclerosis Drug Market by Type
  3. 1.2.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Etomoxir
  5. 1.2.3 Inebilizumab
  6. 1.2.4 IB-MS
  7. 1.2.5 GLX-1112
  8. 1.2.6 DC-TAB
  9. 1.2.7 Others
  10. 1.3 Secondary Progressive Multiple Sclerosis Drug Market by Application
  11. 1.3.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Secondary Progressive Multiple Sclerosis Drug Market Dynamics
  1. 2.1 Secondary Progressive Multiple Sclerosis Drug Industry Trends
  2. 2.2 Secondary Progressive Multiple Sclerosis Drug Industry Drivers
  3. 2.3 Secondary Progressive Multiple Sclerosis Drug Industry Opportunities and Challenges
  4. 2.4 Secondary Progressive Multiple Sclerosis Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region
  3. 3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region
  9. 3.4.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Secondary Progressive Multiple Sclerosis Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers
  2. 4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers
  6. 4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Secondary Progressive Multiple Sclerosis Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers, Product Type & Application
  13. 4.7 Global Secondary Progressive Multiple Sclerosis Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Secondary Progressive Multiple Sclerosis Drug Market CR5 and HHI
  16. 4.8.2 2025 Secondary Progressive Multiple Sclerosis Drug Tier 1, Tier 2, and Tier 3
5 Secondary Progressive Multiple Sclerosis Drug Market by Type
  1. 5.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type
  2. 5.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type
  6. 5.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Type
6 Secondary Progressive Multiple Sclerosis Drug Market by Application
  1. 6.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application
  2. 6.1.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application
  6. 6.2.1 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Secondary Progressive Multiple Sclerosis Drug Price by Application
7 Company Profiles
  1. 7.1 AB Science SA
  2. 7.1.1 AB Science SA Company Information
  3. 7.1.2 AB Science SA Business Overview
  4. 7.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  6. 7.1.5 AB Science SA Recent Developments
  7. 7.2 Actelion Ltd
  8. 7.2.1 Actelion Ltd Company Information
  9. 7.2.2 Actelion Ltd Business Overview
  10. 7.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  12. 7.2.5 Actelion Ltd Recent Developments
  13. 7.3 F. Hoffmann-La Roche Ltd.
  14. 7.3.1 F. Hoffmann-La Roche Ltd. Company Information
  15. 7.3.2 F. Hoffmann-La Roche Ltd. Business Overview
  16. 7.3.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  18. 7.3.5 F. Hoffmann-La Roche Ltd. Recent Developments
  19. 7.4 Genzyme Corporation
  20. 7.4.1 Genzyme Corporation Company Information
  21. 7.4.2 Genzyme Corporation Business Overview
  22. 7.4.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  24. 7.4.5 Genzyme Corporation Recent Developments
  25. 7.5 Glialogix, Inc.
  26. 7.5.1 Glialogix, Inc. Company Information
  27. 7.5.2 Glialogix, Inc. Business Overview
  28. 7.5.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  30. 7.5.5 Glialogix, Inc. Recent Developments
  31. 7.6 Immune Response BioPharma, Inc.
  32. 7.6.1 Immune Response BioPharma, Inc. Company Information
  33. 7.6.2 Immune Response BioPharma, Inc. Business Overview
  34. 7.6.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  36. 7.6.5 Immune Response BioPharma, Inc. Recent Developments
  37. 7.7 Innate Immunotherapeutics Ltd
  38. 7.7.1 Innate Immunotherapeutics Ltd Company Information
  39. 7.7.2 Innate Immunotherapeutics Ltd Business Overview
  40. 7.7.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  42. 7.7.5 Innate Immunotherapeutics Ltd Recent Developments
  43. 7.8 Kyorin Pharmaceutical Co., Ltd.
  44. 7.8.1 Kyorin Pharmaceutical Co., Ltd. Company Information
  45. 7.8.2 Kyorin Pharmaceutical Co., Ltd. Business Overview
  46. 7.8.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  48. 7.8.5 Kyorin Pharmaceutical Co., Ltd. Recent Developments
  49. 7.9 Mallinckrodt Plc
  50. 7.9.1 Mallinckrodt Plc Company Information
  51. 7.9.2 Mallinckrodt Plc Business Overview
  52. 7.9.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  54. 7.9.5 Mallinckrodt Plc Recent Developments
  55. 7.10 MedDay SA
  56. 7.10.1 MedDay SA Company Information
  57. 7.10.2 MedDay SA Business Overview
  58. 7.10.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  60. 7.10.5 MedDay SA Recent Developments
  61. 7.11 MedImmune, LLC
  62. 7.11.1 MedImmune, LLC Company Information
  63. 7.11.2 MedImmune, LLC Business Overview
  64. 7.11.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  66. 7.11.5 MedImmune, LLC Recent Developments
  67. 7.12 Merck KGaA
  68. 7.12.1 Merck KGaA Company Information
  69. 7.12.2 Merck KGaA Business Overview
  70. 7.12.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  72. 7.12.5 Merck KGaA Recent Developments
  73. 7.13 Meta-IQ ApS
  74. 7.13.1 Meta-IQ ApS Company Information
  75. 7.13.2 Meta-IQ ApS Business Overview
  76. 7.13.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  78. 7.13.5 Meta-IQ ApS Recent Developments
  79. 7.14 Opexa Therapeutics, Inc.
  80. 7.14.1 Opexa Therapeutics, Inc. Company Information
  81. 7.14.2 Opexa Therapeutics, Inc. Business Overview
  82. 7.14.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  84. 7.14.5 Opexa Therapeutics, Inc. Recent Developments
  85. 7.15 Xenetic Biosciences (UK) Limited
  86. 7.15.1 Xenetic Biosciences (UK) Limited Company Information
  87. 7.15.2 Xenetic Biosciences (UK) Limited Business Overview
  88. 7.15.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  90. 7.15.5 Xenetic Biosciences (UK) Limited Recent Developments
  91. 7.16 Biogen, Inc.
  92. 7.16.1 Biogen, Inc. Company Information
  93. 7.16.2 Biogen, Inc. Business Overview
  94. 7.16.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  96. 7.16.5 Biogen, Inc. Recent Developments
  97. 7.17 Novartis AG
  98. 7.17.1 Novartis AG Company Information
  99. 7.17.2 Novartis AG Business Overview
  100. 7.17.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolio
  102. 7.17.5 Novartis AG Recent Developments
8 North America
  1. 8.1 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  2. 8.1.1 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2032)
  5. 8.2 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 8.2.1 North America Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2032)
  9. 8.3 North America Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  10. 8.3.1 North America Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Secondary Progressive Multiple Sclerosis Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  2. 9.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2032)
  5. 9.2 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 9.2.1 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2032)
  9. 9.3 Europe Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  10. 9.3.1 Europe Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Secondary Progressive Multiple Sclerosis Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  2. 10.1.1 China Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  4. 10.1.3 China Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2032)
  5. 10.2 China Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 10.2.1 China Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 10.2.3 China Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  2. 11.1.1 Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2032)
  5. 11.2 Asia Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 11.2.1 Asia Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2032)
  9. 11.3 Asia Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  10. 11.3.1 Asia Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Secondary Progressive Multiple Sclerosis Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Secondary Progressive Multiple Sclerosis Drug Market Size by Type
  2. 12.1.1 SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Secondary Progressive Multiple Sclerosis Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Secondary Progressive Multiple Sclerosis Drug Market Size by Application
  6. 12.2.1 SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Secondary Progressive Multiple Sclerosis Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Secondary Progressive Multiple Sclerosis Drug Market Size by Country
  10. 12.3.1 SAMEA Secondary Progressive Multiple Sclerosis Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Secondary Progressive Multiple Sclerosis Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Secondary Progressive Multiple Sclerosis Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Secondary Progressive Multiple Sclerosis Drug Value Chain Analysis
  2. 13.1.1 Secondary Progressive Multiple Sclerosis Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Secondary Progressive Multiple Sclerosis Drug Production Mode & Process
  6. 13.2 Secondary Progressive Multiple Sclerosis Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Secondary Progressive Multiple Sclerosis Drug Distributors
  9. 13.2.3 Secondary Progressive Multiple Sclerosis Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst